Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638942 | 0.86 | CNR1 (0.61) | CNR1L3MBTL1CNR2 | |
| SCHEMBL29388220 | 0.86 | CNR1 (0.61) | CNR1L3MBTL1CNR2 | |
| SCHEMBL30259591 | 0.80 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL9501537 | 0.75 | HTR2A (0.54) | CNR1CNR2 | |
| SCHEMBL29362376 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL10093017 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4106102 | 0.72 | ALDH1A1 (0.68) | L3MBTL1 | |
| SCHEMBL12643065 | 0.71 | CNR2 (0.52) | CNR1CNR2 | |
| SCHEMBL31012122 | 0.71 | CYP1A2 (0.56) | CNR1CNR2 | |
| SCHEMBL4850585 | 0.71 | CYP1A2 (0.56) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | OPRM1, OPRL1, OPRK1 | CNR1 7/4885L3MBTL1 1748/4885CNR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.